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Background: Increasing evidence has shown that an elevated a level of homocysteine (Hcy) in the blood
is related to several diseases. Over the last few years, studies have demonstrated creatine (Cr) synthesis
and Hcy formation are metabolically connected; and Cr supplementation can decrease Hcy blood levels
in different situations. This data however is inconsistent and still controversial.
Objective: The aim of this critical review with meta-analysis was to discuss and ascertain the effects of Cr
supplementation on blood Hcy levels.
Method: A review was conducted according to the PRISMA guidelines using PubMed Discuss and Scielo
online databases to identify relevant studies through November 2015. RevMan was used to calculate the
effect size of the change in Hcy plasma/serum concentration from baseline to post-supplementation with
Cr vs. placebo groups. Weighted mean differences were calculated using random effect models.
Results: Cr supplemented trials were divided into two subgroups according to whether the experimental
design included animals or humans participants. Overall, 14 studies were included in the meta-analysis.
The six rodent included studies reported decreased plasma Hcy concentration after Cr supplementation
with a mean effect size equal to2.43 mmol/l (95% CI: 3.60, 1.26, P < 0.01). The humans studies involved
483 participants (242 Cr and 241 placebo supplemented subjects) and indicated no changes in plasma
Hcy concentration after Cr supplementation compared to placebo (0.09 mmol/l, 95% CI: 0.47, 0.66,
P ¼ 0.18).
Conclusions: Our data demonstrated Cr supplementation is effective in decrease Hcy blood concentration
in rats; the same effect however, is not demonstrated humans studies. Human and rats particularities in
Hcy metabolism and poorly controlled humans studies may contribute to the divergence of results.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Homocysteine (Hcy) is a sulfur amino acid synthesized in the
liver as a byproduct of methioninemetabolism [1]. Hcy has recently
gained attention in the literature due to its association with several
diseases that may increase the risk of mortality [2,3]. Humphrey
et al. [4] demonstrated that each increase of 5 mmol/l in plasma Hcy
concentration increased the risk of cardiovascular events by
approximately 20%. Bostom et al. [5] demonstrated elevated blood
Hcy concentration is independently associated with an elevated
risk of mortality (54% for all-cause mortality and 52% for cardio-
vascular mortality).
Creatine (Cr) occurs naturally in food, especially in meat and
ﬁsh. In human omnivores, one-half of Cr required is provided in the
diet and the remainder is endogenously synthesized [6]. Recent
studies have shown Cr synthesis and Hcy formation are metaboli-
cally connected (Fig. 1) [7,8]. Cr synthesis involves the reversible
transfer of the amidino group of arginine to glycine to form gua-
nidinoacetic acid (GAA) and ornithine in a reaction catalyzed by the
enzyme arginine: glycine amidinotransferase (AGAT), which is very
active in kidneys. Next, the irreversible transfer of a methyl group
from S-adenosylmethionine (SAM) to GAA is catalyzed by the
enzyme guanidinoacetate N-methyltransferase (GAMT) in the liver
[6] and Cr is formed. SAM acts primarily as a universal methyl donor
in the synthesis of several others methylated compounds such as
neurotransmitters (adrenaline, noradrenaline), DNA, RNA, phos-
phatidylcholine and others. A byproduct of these methylationFig. 1. Schematic presentation of the interaction of Hcy and Cr metabolism in rats. 1) action
formation as the ﬁrst step of Cr synthesis; 2) the irreversible transfer of a methyl group from
methyltransferase (GAMT) in the liver; 3) Cr/PCr muscle system; 4) an increase in Cr intake d
(reaction 2); 5) remethylation pathway; 6) transsulfuration pathway. THF, tetrahydrofolate; M
methyl-transferase; CbS, cystathionine-b-synthase; GSH, reduced glutathione.reactions is S-adenosylhomocysteine, which is hydrolyzed to
adenosine and Hcy. Thus, Cr synthesis and Hcy formation are
metabolically linked by methyl metabolism. Previous studies have
shown that Cr supplementation downregulates AGAT activity [7,9]
and the endogenous synthesis of Cr; because Cr synthesis is
responsible for a considerable consumption of SAM (at least 40%)
and Hcy formation [7,10], Cr supplementation leads to reduced
Hcys formation in rats [7,10e12]. There have only been a small
number of studies regarding the effect of Cr supplementation in
humans, and the results from these studies were quite inconsistent.
Given the inconsistence of the published data, it is important to
investigatewhether Cr supplementationmodulate Hcymetabolism
in different situations. The increasing number of published studies
allows us to apply strict methodological analysis and summarize
the main results. Thus, we propose a meta-analysis approach to
provide a statistical summary of comparable studies in order to
consolidate a quantitative review of the effects of Cr supplemen-
tation on blood Hcy concentration.
2. Methods
2.1. Search approach and study selection
This review was conducted in accordance with PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-
analyses) statement guidelines [13,14]. The PubMed database was
searched for English-language articles, using the combination ofof kidney L-arginine: glycine amidinotransferase AGAT for guanidineacetic acid (GAA)
S-adenosylmethionine (SAM) to GAA is catalyzed by the enzyme guanidinoacetate N-
own-regulates kidney AGAT in reaction 1 and decreases methyl ﬂux for Hcy formation
S, methionine synthase; GNMT, glycine N-methyltransferase; GAMT, guanidinoacetate
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mentation” through November 2015. Any caseecontrol, cross-
sectional study, clinical trial or cohort study that assayed the
blood concentrations of Hcy in rodents and/or humans using Cr
supplementation condition were ﬁrst analyzed. The references of
all review articles and original papers were examined and cross-
checked. Relevant articles cited in the publications were carefully
reviewed and included in the meta-analysis if they matched the
inclusion criteria. After exclusion of duplicate publications, the
identiﬁed articles were included in the review if they matched the
following criteria: 1) available in English, 2) performed in rodents
and/or humans, 3) performed a Cr supplementation design, and 4)
contained quantitative information regarding Hcy plasma or serum
concentrations. The records were excluded if they presented the
following characteristics: 1) provided a review and/or meta-
analysis, 2) studies without a placebo/control group. The selection
criteria were not limited by supplementation duration, Cr supple-
mentation dosage, included physical exercise group or interven-
tion, B-vitamins intake control. Two authors (RD and FTR)
independently conducted this review search using the same search
strategy. A total of 44 articles were identiﬁed during the initial
search process. The search strategy considered twomain outcomes:
1) Effects of Cr supplementation on Hcy plasma/serum concentra-
tions in rodents, and 2) in humans. The study selection process is
described in Fig. 2.
2.2. Data extraction
The following data were extracted from the articles included in
the rodent meta-analysis: authors and year of publication; country
where the study was conducted; animal model; supplementation
regime; principal results (Table 2). When humans were considered,
the following data were extracted: authors and year of publication;
country where the study was conducted; number of subjects
included in the study; participants' characteristics; supplementa-
tion regimen; and principal results (Table 3). All meta-analysis
procedures were conducted as described by Stroup et al. [15].
2.3. Data analyses
Meta-analysis was conducted using Review Manager Software
(RevMan software package version 5.0). RevMan was used to
calculate the effect size of the change in Hcy plasma/serum con-
centration from baseline to post-supplementation with Cr vs. pla-
cebo groups in human studies. When rodent studies were analyzed,
RevMan was used to calculate the effect size of the change in Hcy
plasma/serum concentration from Cr supplement group compared
to comtrol. In circumstances when the change frombaseline data or
corresponding standard deviations were not available, these values
were calculated using standard statistical methods assuming a
correlation of 0.50 between the baseline and post-intervention
scores within each subject [16]. In situations where studies re-
ported standard error, the values were converted to standard de-
viation (SD). For studies with non-parametric data reporting
median and range, the equations of Hozo et al. [17] were used to
estimate mean and SD.
Data from all included studies were used to calculate the
weighted mean difference and 95% conﬁdence interval (CI) using a
continuous random effects model. Weighted percentages were
based on the sample sizes of respective studies. Statistical signiﬁ-
cance was assumed as p < 0.05 in a Z test analysis, to examine
whether effect size was signiﬁcantly different from zero. Study
heterogeneity was evaluated using the I2 statistic and Cochrane's Q.
Values of I2 higher than 50 and 75% were considered moderate and
high heterogeneity. For Cochrane's Q, signiﬁcant heterogeneity wasconsidered to exist when the Q value exceeds the degrees of
freedom (df) of the estimate. When meta-analysis was considered
to be moderate to high heterogeneity, and the random-effects
model was used [18], publication bias was tested visually using a
funnel plot.
3. Results
3.1. Study search
The initial search resulted in 44 abstracts; Fig. 2 describes how
they are arranged. First, repeated studies and reviews were
excluded (n ¼ 10). Thirty-four studies were then assessed for
eligibility by applying the inclusion and exclusion criteria, as a
result of which 15 studies were excluded because they did not
present adequate information to calculate effect size or aimed to
correlate Hcy and Cr levels, only. Then, nineteen articles received
more detailed evaluation. After extensive discussions between the
authors, 5 studies were excluded; Table 1 summarizes the excluded
articles. Finally, a total of 14 articles were identiﬁed for inclusion in
the meta-analysis: six rodent and eight human studies. Table 2
describes the characteristics of the 6 animals studies included
and Table 3 summarizes the 8 humans studies included in the
meta-analysis. PRISMA ﬂow diagram of the study selection process
is presented in Fig. 2.
3.2. Overview of included studies
All rodent studies included in the meta-analysis used rats. Cr
supplementation regimens were diverse in supplementation
duration (from 2 to 4 weeks) and dosage (from 0.4 to 2% added to
the diet). Cr supplementation was able to decrease Hcy in all rat
studies identiﬁed under different situations including healthy
conditions [10,7]; elevated Hcy induced by pathological models
including chronic renal failure [11] and fatty-liver disease [12,24];
and elevated Hcy induced by high-intensity exercise [25]
(Table 2).
Sample size of human studies ranged from 5 to 101 subjects per
treatment. Five of the human studies included healthy participants;
others included Hemodialysis [26], coronary artery disease [27] and
Rett syndrome [28] patients. Four studies used long-term Cr sup-
plementation [26,28e30] ranging from 1 to 6 months. Only two
studies used short-tern supplementation regimens from 3 to 7 days
of supplementation [27,31], all of them with high Cr dosages
(>20 g/d). Other two used the classical supplementation protocol
proposed by Hultman et al. [32] including load and maintenance
supplementation phases [33,34] (Table 3).
3.3. Meta-analysis
The six rodent studies included reported decreased plasma Hcy
concentration after Cr supplementationwith an average effects size
of 2.43 mmol/l (95% CI: 3.60, 1.26, P < 0.01; Fig. 3) and a
moderate degree of heterogeneity (I2 ¼ 67%; Cochrane's Q ¼ 15.1,
df ¼ 5, P < 0.01). Funnel plot inspection demonstrated symmetric
distribution and an absence of publication bias. Conversely, only 2
human studies agree that Cr supplementation decreases Hcy
plasma concentration, 5 demonstrated no changes and 1 found
increased plasma Hcy levels after Cr supplementation. The eight
human studies included a total of 483 participants (242 Cr and 241
placebo supplemented subjects). The meta-analysis demonstrated
no changes in plasma Hcy concentration of humans after Cr sup-
plementation with a mean effect size equal to 0.09 mmol/l (95%
CI: 0.47, 0.66, P ¼ 0.75; Fig. 3) and a low degree of heterogeneity
(I2 ¼ 4%; Cochrane's Q ¼ 7.31, df ¼ 7, P ¼ 0.40). Funnel plot
Fig. 2. PRISMA ﬂow diagram of the study selection process. After careful discussion between the 2 reviewers, two outcomes were identiﬁed and included in the meta-analysis.
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lication bias.
4. Discussion
The present study sought to investigate whether Cr supple-
mentation inﬂuences blood levels of Hcy through a meta-analysis.
We conducted the analysis using two pre-speciﬁed outcomes:
studies including rodents and humans. The rodent studies meta-analysis revealed Cr supplementation is able to decrease Hcy
plasma concentration; the magnitude of the Hcy plasma decrease
was 2.43 mmol/l (~30%, Fig. 3). This observation is particularly
relevant considering the moderate heterogeneity among the
studies with regard to the supplementation period and dosage
(Table 2). In addition, Cr could decrease or prevent elevated Hcy
under different animal models such as increased Hcy induced by
acute exercise [25], and some pathological conditions such as renal
chronic failure [11] and fatty-liver disease [24]. In contrast, meta-
Table 1
Articles (n ¼ 12) excluded from the study.
Study Aim Reason for exclusion
Norlund et al.,
1998 [19]
To explore the relation between plasma Hcy concentration and serum creatinine in health subjects Did not included Cr supplementation
intervention
Navratil et al.,
2010 [20]
To investigate the levels of various compounds in blood or urine, and body parameters connected
with CR metabolism.
Absence of a placebo/control group
Petr et al., 2013
[21]
To evaluate homocysteinemia following Cr supplementation in relation to MTHFR 677C/T genotype. Absence of a placebo/control group
Moraes et al.,
2014 [22]
To investigated the effects of Cr supplementation on the systemic microcirculation and on Hcy levels
in healthy young individuals.
Absence of a placebo/control group
Peters et al., 2015
[23]
To determine whether folic acid and/or creatine supplementation lowers blood arsenic in an arsenic-
exposed Bangladeshi population.
Lack of Hcy concentration post Cr
supplementation intervention
Table 2
Characteristics of rodents studies included in the meta-analysis.
Study Country Specie Animal model Supplementation regimen Principal results
Stead et al.,
2001 [7]
Canada Sprague
eDawley
rats
Healthy rats 0.4% wt/wt Cr monohydrate added
to AIN-93 diet for 2 wk
Cr-supplemented rats exhibited a signiﬁcantly lower (~25%) plasma Hcy
level compared to control.
Taes et al.,
2003
[11]
Belgium Wistar
rats
Nephrectomized rats 2% wt/wt Cr monohydrate added to
the diet for 2 wk
Plasma Hcy was higher in nephrectomized rats. Cr supplementation reduced
(18%) Hcy in nephrectomized compared to nephrectomized control dietefed
rats
Deminice
et al.,
2009
[10]
Brazil Wistar
rats
Healthy rats 0.4% wt/wt Cr monohydrate added
to AIN-93 diet for 4 wk
Plasma Hcy and TBARS were signiﬁcantly lower in CR-supplemented group
compared to control
Deminice
et al.,
2011
[25]
Brazil Wistar
rats
Acute exercised rats 2% wt/wt Cr monohydrate added to
AIN-93 diet for 4 wk
Cr supplementation inhibited increased Hcy plasma concentration induced
by acute exercise.
Deminice
et al.,
2011
[12]
Canada Sprague
eDawley
rats
Fatty liver induced
by high-fat diet
1% wt/vol Cr monohydrate added to
high-fat liquid diet for 3 wk
Cr-supplemented rats had lower (~25%) plasma Hcy level compared to
control; high-fat diet did not changed Hcy plasma levels
Deminice
et al.,
2015
[24]
Brazil Wistar
rats
Fatty liver induced
by choline deﬁcient
diet
2% wt/wt Cr monohydrate added to
AIN-93 choline-deﬁcient diet for
4 wk
Cr supplementation prevented increased Hcy plasma levels and fatty liver
induced by a choline-deﬁcient diet
wt, weight; vol, volume; wk, week.
Table 3
Characteristics of human studies included in the meta-analysis.
Study Country Total
n (M/
F)
Participants characteristics Supplementation regimen Principal results
Steenge et al.,
2001 [33]
Netherlands 12 (0/
12)
Moderated active woman
aged 19e38 years
20 g/d for 5 days, followed by another 8 wk with
3 g/d
Cr supplementation resulted in a small non-
signiﬁcant decrease in HCy plasma levels
Korzun 2004
[29]
USA 16 (7/
9)
Apparently healthy university
volunteers
Cr supplementation was twice the daily
creatinine excretion for 4 wk
Cr supplementation lowered Hcy after 4 wk period
Taes et al.,
2004 [26]
Belgium 49
(24/
21)
Hemodialysis patients,
performed dialysis 4e5 h, 3
times weekly
2 g/d for 4 wk in a placebo controlled, double-
blind and crossover design (4 wk washout)
All hemodialysis patients had elevated Hcy; Cr did
not affect Hcy plasma concentration.
Jahangir et al.,
2009 [27]
USA 55 () Subjects with proven
coronary artery disease
21 g/d for 3 days in a placebo controlled double-
blind manner
Cr supplementation (alone or in combination with
L-arginine) was associated with an 11e20% increase
in Hcy.
Freilinger
et al., 2011
[28]
Austria 21 (0/
21)
Patients with Rett syndrome 200mg/kg/d for 6months in a placebo controlled,
double-blind and crossover design (1 month
washout)
Plasma Hcy had no signiﬁcant changes after Cr
supplementation
Deminice
et al., 2013
[31]
Brazil 23
(23/0)
Healthy and well-trained and
young soccer players
0.3 g/kg/d for 7 days in a double-blind, placebo
controlled manner
Hcy was signiﬁcant increased (18%) after acute
exercise; Cr supplementation did not change Hcy
plasma level
Bereket-Yucel
et al., 2015
[34]
Turkey 16
(16/0)
Non-vegetarian university
students
25 g/d for 5 days followed by another 51 days
with 5 g/d
Hcy was signiﬁcant lower in Cr supplemented
resistance exercised subjects compared to placebo
Peters et al.,
2015 [30]
Bangladesha 203
(103/
101)
Adults between 20 and 65
years of age
3 g/d for 12 wk in a randomized, double-blind,
placebo-controlled trial
Cr supplementation decreased plasma GAA but not
Hcy
G, grams; d, day; wk, week; GAA, guanidineacetic acid.
a Authors from USA.
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Fig. 3. Meta-analysis performed on the effects of Cr supplementation on blood Hcy concentration in rodents and humans (mean ± SD). For rodent studies, effect size was calculated
using the change in Hcy plasma/serum concentration from Cr supplement group compared to control. For humans, effect size of the change in Hcy plasma/serum concentration
from baseline to post-supplementation with Cr vs placebo groups is presented. Results are expressed as weighted mean difference (WMD) of Hcy (mmol/l) and 95% conﬁdence
intervals (95% CI).
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concentration after Cr supplementation (Fig. 3). Indeed, the effect
of Cr supplementation on Hcy blood levels in humans is demon-
strated to be inconsistent. Our review demonstrated two human
studies found decreased Hcy after Cr supplementation [29,34], ﬁve
demonstrated no changes [26,28,30,31,33], and one [27] demon-
strated increased Hcy after Cr supplementation.
Studies have demonstrated that Cr synthesis is responsible for
considerable SAM consumption in the liver and Hcy formation [6].
Stead et al. [8] based on studies using stable isotopes to determine
the methylation ﬂux, demonstrated that the synthesis of phos-
phatidylcholine and Cr are both the major consumers of SAM in the
liver; and Cr is responsible for at least 40% of the methylation de-
mand and consequently for Hcy formation. Cr supplementation
increases plasma, muscle and liver Cr concentration. As a conse-
quence, a remarkable (~80%) down-regulation of renal AGAT ac-
tivity and decreased GAA concentration are found [12], showing a
reduction in the endogenous formation of Cr [7,10,12]. This Cr
synthesis suppression by Cr supplementation leads to decreasing
GAA availability and SAM consumption in rats, decreasing Hcy
formation as consequence [7,10,12] (Fig. 1). Stead et al. [7] studied
how methylation demand and Hcy formation were modulated by
Cr and GAA intake, using rats receiving either 0.4% Cr, 0.36% GAA or
a control diet. Hcy levels were reduced 25% by Cr, and increased 50%
with GAA, while plasma methionine levels were unchanged.
The divergence between rodent and human studies found in our
meta-analysis seems paradoxical since the Cr synthesis suppres-
sion by Cr supplementation appears be the same in rats and
humans. Although no human studies have determined renal AGAT
activity after Cr supplementation, Derave et al. [35] showed
decreased GAA (50%) after 1 week of Cr supplementation, beside an
inverse relationship between plasma Cr and GAA levels measured
in 10-week Cr-supplemented humans. More recently, Deminice
et al. [31] and Peters et al. [30] demonstrated ~33% and ~11% sig-
niﬁcant decreased GAA plasma concentration after Crsupplementation, respectively. Controversially, none of the cited
human studies demonstrated that Cr supplementation lowers
plasma Hcy. Some studies have pointed differences in creatine and
Hcy metabolism between humans and rats and try to explain the
controversy in the results [36e39]. As an example, in rats, around
30% of plasma Hcy is protein bound. In normal humans, however,
80% of total Hcy bound to formmixed disulﬁde and the remaining is
found in free form [36]. In addition, human but not rat kidney
contains BHMT activity. Conversely, kidney of humans presents
very small activity of cystathionine-b-synthase compared with rats
[38]. However, whether these differences are responsible for the
different responses of Cr supplementation on Hcy metabolism in
rats and humans is not known.
Despite the metabolic differences presented above, we consider
the inconsistence regarding supplementation protocol, presence of
disease, age and gender of the studied population, presence of
exercise protocols, control of B-vitamins intake or vitamins sup-
plementation contribute signiﬁcantly to the controversy in the re-
sults found between rats and human studies. The low number of
controlled studies for inclusion in human outcome analysis may
contribute to the discrepancy in the results and appears to be the
major limitation of the present study. In addition, differences in Cr
supplementation dosage may be also considered. Studies from our
laboratory demonstrated a Hcy-lowering effect with 3.1 g/kg/d of Cr
[12], which is appreciably higher than the ~0.3 g/kg/d performed in
humans studies and classically proposed for humans [32,40]. It
should be recognized, however, the allometric scaling factors be-
tween rats and humans. In general, mass-speciﬁc metabolic rate
scales as the 0.75 exponent of mass. Therefore, a 300 g rat has ~4
times the mass-speciﬁc metabolic rate of a 70-kg human. When
expressed on this physiological basis, the rats received 2e3 fold the
Cr supplementation recommended for humans in load phase
(~0.3 g/kg/d). Peters et al. [30] considers the hypothesis that Cr
dosage used in human studies did not sufﬁciently inhibit AGAT.
Indeed, rats and human studies must be compared with caution.
R. Deminice, F.T. Rosa / Journal of Nutrition & Intermediary Metabolism 3 (2016) 50e57565. Conclusion
Over the last few years, interest in Cr supplementation has
increased markedly in the medical ﬁeld because of the beneﬁcial
effects found in a number of muscular, neurological and metabolic
diseases [41]. Ourmeta-analysis revealed that studies conducted on
animals have demonstrated that inhibition of the endogenous
methylation demand by Cr supplementation can reduce Hcy levels,
but these results have not been reliably reproduced in humans.
Human and rats particularities in Hcy metabolism have been
speculated as the reason for differences in the results. However,
inconsistence regarding supplementation protocol, presence of
disease, age and gender of the studied population, presence of
exercise protocols, and intake control or supplementation with B-
vitamins also may contribute signiﬁcantly to the controversy in the
results found between rats and human studies.
Funding source
RD is supported by Brazilian grants from Capes PVE
88881.068035/2014-01 and FUNDAÇ~AO ARAUCARIA - CONV. 184/
2013.
Disclosure
Disclosure none.
Author's contributions
RD and FTR designed the project; RD and FTR conducted search;
RD and FTR analyzed data; RD and FTR wrote the paper; RD had
primary responsibility for ﬁnal content. All authors read and
approved the ﬁnal manuscript.
Conﬂict of interest
None.
References
[1] J. Selhub, Homocysteine metabolism, Annu. Rev. Nutr. 19 (1999) 217e246.
PMID: 10448523.
[2] S. Seshadri, A. Beiser, J. Selhub, P.F. Jacques, I.H. Rosenberg, R.B. D'Agostino, et
al., Plasma homocysteine as a risk factor for dementia and Alzheimer's disease,
N. Engl. J. Med. 14 (346) (2002) 476e483.
[3] M. Suliman, P. Stenvinkel, A.R. Qureshi, K. Kalantar-Zadeh, P. Barany,
O. Heimburger, et al., The reverse epidemiology of plasma total homocysteine
as a mortality risk factor is related to the impact of wasting and inﬂammation,
Nephrol. Dial. Transpl. 22 (2007) 209e217.
[4] L.L. Humphrey, R. Fu, K. Rogers, M. Freeman, M. Helfand, Homocysteine level
and coronary heart disease incidence: a systematic review and meta-analysis,
Mayo Clin. Proc. 83 (2008) 1203e1212.
[5] A.G. Bostom, H. Silbershatz, I.H. Rosenberg, J. Selhub, R.B. D'Agostino,
P.A. Wolf, et al., Nonfasting plasma total homocysteine levels and all-cause
and cardiovascular disease mortality in elderly Framingham men and
women, Arch. Intern Med. 24 (159) (1999) 1077e1080.
[6] J.T. Brosnan, R.P. da Silva, M.E. Brosnan, The metabolic burden of creatine
synthesis, Amino Acids 40 (5) (2011 May) 1325e1331.
[7] L.M. Stead, K.P. Au, R.L. Jacobs, M.E. Brosnan, J.T. Brosnan, Methylation demand
and homocysteine metabolism: effects of dietary provision of creatine and
guanidinoacetate, Am. J. Physiol. Endocrinol. Metab. 281 (5) (2001 Nov)
E1095eE1100.
[8] L.M. Stead, J.T. Brosnan, M.E. Brosnan, D.E. Vance, R.L. Jacobs, Is it time to
reevaluate methyl balance in humans? Am. J. Clin. Nutr. 83 (1) (2006 Jan)
5e10.
[9] R.P. da Silva, I. Nissim, M.E. Brosnan, J.T. Brosnan, Creatine synthesis: hepatic
metabolism of guanidinoacetate and creatine in the rat in vitro and in vivo,
Am. J. Physiol. Endocrinol. Metab. 296 (2) (2009 Feb) E256eE261.
[10] R. Deminice, G.V. Portari, H. Vannucchi, A.A. Jordao, Effects of creatine sup-
plementation on homocysteine levels and lipid peroxidation in rats, Br. J.
Nutr. 102 (1) (2009 Jul) 110e116.
[11] Y.E. Taes, J.R. Delanghe, A.S. De Vriese, R. Rombaut, J. Van Camp, N.H. Lameire,Creatine supplementation decreases homocysteine in an animal model of
uremia, Kidney Int. 64 (4) (2003 Oct) 1331e1337.
[12] R. Deminice, R.P. da Silva, S.G. Lamarre, C. Brown, G.N. Furey, S.A. McCarter,
A.A. Jordao, K.B. Kelly, K. King-Jones, R.L. Jacobs, M.E. Brosnan, J.T. Brosnan,
Creatine supplementation prevents the accumulation of fat in the livers of rats
fed a high-fat diet, J. Nutr. 141 (10) (2011 Oct) 1799e1804.
[13] N. Panic, E. Leoncini, G. de Belvis, W. Ricciardi, S. Boccia, Evaluation of the
endorsement of the preferred reporting items for systematic reviews and
meta-analysis (PRISMA) statement on the quality of published systematic
review and meta-analyses, PloS One 8 (2013) e83138.
[14] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement, PLoS Med. 6
(2009) e1000097.
[15] D.F. Stroup, J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, et al.,
Meta-analysis of observational studies in epidemiology: a proposal for
reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE)
group, JAMA 283 (2000) 2008e2012.
[16] D. Follmann, P. Elliott, I. Suh, J. Cutler, Variance imputation for overviews of
clinical trials with continuous response, J. Clin. Epidemiol. 45 (1992) 769e773.
[17] S.P. Hozo, B. Djulbegovic, I. Hozo, Estimating the mean and variance from the
median, range, and the size of a sample, BMC Med. Res. Methodol. 5 (2005) 13.
[18] J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman, Measuring inconsistency
in meta-analyses, BMJ 327 (2003) 557e560.
[19] L. Norlund, A. Grubb, G. Fex, H. Leksell, J.E. Nilsson, H. Schenck, B. Hultberg,
The increase of plasma homocysteine concentrations with age is partly due to
the deterioration of renal function as determined by plasma cystatin C, Clin.
Chem. Lab. Med. 36 (3) (1998 Mar) 175e178.
[20] T. Navratil, E. Kohlíkova, M. Petr, D. Pelclova, M. Heyrovský, K. Pristoupilova,
Supplemented creatine induces changes in human metabolism of thio-
compounds and one- and two-carbon units, Physiol. Res. 59 (3) (2010)
431e442.
[21] M. Petr, M. Stefﬂ, E. Kohlíkova, Effect of the MTHFR 677C/T polymorphism on
homocysteinemia in response to creatine supplementation: a case study,
Physiol. Res. 62 (6) (2013 Dec 20) 721e729.
[22] Rd Moraes, D. Van Bavel, B.S. Moraes, E. Tibiriça, Effects of dietary creatine
supplementation on systemic microvascular density and reactivity in healthy
young adults, Nutr. J. 13 (1) (2014 Dec 15) 115.
[23] B.A. Peters, M.N. Hall, X. Liu, F. Parvez, T.R. Sanchez, A. van Geen, J.L. Mey,
A.B. Siddique, H. Shahriar, M.N. Uddin, T. Islam, O. Balac, V. Ilievski, P. Factor-
Litvak, J.H. Graziano, M.V. Gamble, Folic acid and creatine as therapeutic ap-
proaches to lower blood arsenic: A randomized controlled trial, Environ.
Health Perspect. 123 (12) (2015 Dec) 1294e1301.
[24] R. Deminice, G.S. de Castro, L.V. Francisco, L.E. da Silva, J.F. Cardoso,
F.T. Frajacomo, B.G. Teodoro, L. Dos Reis Silveira, A.A. Jordao, Creatine sup-
plementation prevents fatty liver in rats fed choline-deﬁcient diet: a burden
of one-carbon and fatty acid metabolism, J. Nutr. Biochem. 26 (4) (2015 Apr)
391e397.
[25] R. Deminice, H. Vannucchi, L.M. Simoes-Ambrosio, A.A. Jordao, Creatine sup-
plementation reduces increased homocysteine concentration induced by
acute exercise in rats, Eur. J. Appl. Physiol. 111 (2011) 2663e2670.
[26] Y.E. Taes, J.R. Delanghe, D. De Bacquer, M. Langlois, L. Stevens, I. Geerolf,
N.H. Lameire, A.S. De Vriese, Creatine supplementation does not decrease total
plasma homocysteine in chronic hemodialysis patients, Kidney Int. 66 (6)
(2004 Dec) 2422e2428.
[27] E. Jahangir, J.A. Vita, D. Handy, M. Holbrook, J. Palmisano, R. Beal, J. Loscalzo,
R.T. Eberhardt, The effect of L-arginine and creatine on vascular function and
homocysteine metabolism, Vasc. Med. 14 (3) (2009 Aug) 239e248.
[28] M. Freilinger, D. Dunkler, I. Lanator, C.B. Item, A. Mühl, B. Fowler,
O.A. Bodamer, Effects of creatine supplementation in Rett syndrome: a ran-
domized, placebo-controlled trial, J. Dev. Behav. Pediatr. 32 (6) (2011)
454e460.
[29] W.J. Korzun, Oral creatine supplements lower plasma homocysteineconcen-
trations in humans, Clin. Lab. Sci. 17 (2) (2004) 102e106.
[30] B.A. Peters, M.N. Hall, X. Liu, F. Parvez, A.B. Siddique, H. Shahriar, M.N. Uddin,
T. Islam, V. Ilievski, J.H. Graziano, M.V. Gamble, Low-Dose Creatine Supple-
mentation Lowers Plasma Guanidinoacetate, but Not Plasma Homocysteine, in
a Double-Blind, Randomized, Placebo-Controlled Trial, J. Nutr. 145 (10) (2015
Oct) 2245e2252.
[31] R. Deminice, F.T. Rosa, G.S. Franco, S.F. da Cunha, E.C. de Freitas, A.A. Jordao,
Short-term creatine supplementation does not reduce increased homocyste-
ine concentration induced by acute exercise in humans, Eur. J. Nutr. 53 (6)
(2014 Sep) 1355e1361.
[32] E. Hultman, K. S€oderlund, J.A. Timmons, G. Cederblad, P.L. Greenhaff, Muscle
creatine loading in men, J. Appl. Physiol. (1985) 81 (1) (1996 Jul) 232e237.
[33] G.R. Steenge, P. Verhoef, P.L. Greenhaff, The effect of creatine and resistance
training on plasma homocysteine concentration in healthy volunteers, Arch.
Intern. Med. 161 (2001) 1455e1456.
[34] S. Bereket-Yücel, Creatine supplementation alters homocysteine level in
resistance trained men, J. Sports Med. Phys. Fit. 55 (4) (2015 Apr) 313e319.
[35] W. Derave, B. Marescau, E. Vanden Eede, B.O. Eijnde, P.P. De Deyn, P. Hespel,
Plasma guanidino compounds are altered by oral creatine supplementation in
healthy humans, J. Appl. Physiol. (1985) 97 (3) (2004 Sep) 852e857.
[36] L.M. Stead, M.E. Brosnan, J.T. Brosnan, Characterization of homocysteine
metabolism in the rat liver, Biochem. J. 15 (350 Pt 3) (2000) 685e692.
[37] P.M. Ueland, Homocysteine species as components of plasma redox thiol
R. Deminice, F.T. Rosa / Journal of Nutrition & Intermediary Metabolism 3 (2016) 50e57 57status, Clin. Chem. 41 (3) (1995) 340e342.
[38] J.T. Brosna, Homocysteine and the kidney, in: R. Carmel, D.W. Jacobsen (Eds.),
Homocysteine in Health and Disease, Cambridge University Press, Cambridge,
2001, pp. 176e184.
[39] A.N. Friedman, A.G. Bostom, J. Selhub, A.S. Levey, I.H. Rosenberg, The kidney
and homocysteine metabolism, J. Am. Soc. Nephrol. 12 (10) (2001)
2181e2189.[40] R.C. Harris, K. S€oderlund, E. Hultman, Elevation of creatine in resting and
exercised muscle of normal subjects by creatinesupplementation, Clin. Sci.
Lond. 83 (3) (1992 Sep) 367e374.
[41] B. Gualano, G.G. Artioli, J.R. Poortmans, A.H. Lancha Junior, Exploring the
therapeutic role of creatine supplementation, Amino Acids 38 (1) (2010 Jan)
31e44.
